Assessment of the efficacy, safety and pharmacokinetics of SKG-02 (Recombinant human TSH) in postoperative diagnosis of well-differentiated thyroid cancer -A japanese prospective, controlled, multicenter open-label study-

Kakuigaku

Volumn 47, Issue 4, 2010, Pages 479-496

  Konishi, Junji ^a   Tamaki, Nagara ^b   Nakada, Kunihiro ^b   Kusakabe, Kiyoko ^c   Maki, Masako ^c   Kanbe, Masako ^c   Higashi, Tatsuya ^d   Endo, Keigo ^e   Ikekubo, Katsuji ^f   Yokoyama, Kunihiko ^g   Kubo, Atsushi ^h   Ishikawa, Naofumi ⁱ  

^a Sugita Genpaku Memorial Obama Municipal Hospital   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY HOSPITAL   (Japan)

^e GUNMA UNIVERSITY HOSPITAL   (Japan)

^f KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^g KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^h KEIO UNIVERSITY HOSPITAL   (Japan)

ⁱ ITO HOSPITAL   (Japan)

Author keywords

Diagnostic whole body scan; Efficacy; Pharmacokinetics; Recombinant human thyroidstimulating hormone; Safety; Serum thyroglobulin testing; SKG 02; Thyrogen

Indexed keywords

DIAGNOSTIC AGENT; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN;

AGED; ARTICLE; ASIAN; BLOOD; CARCINOMA; CLINICAL TRIAL; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; POSTOPERATIVE PERIOD; PROSPECTIVE STUDY; SCINTISCANNING; THYROID TUMOR; THYROIDECTOMY; WHOLE BODY IMAGING;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; PROSPECTIVE STUDIES; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN ALFA; WHOLE BODY IMAGING;

EID: 79551712929     PISSN: 00227854     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Maxon HR, Smith HS: Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am 1990; 19: 685-718.
2. Ozata M, Suzuki S, Miyamoto T, Liu RT, Fierro-Renoy F, Degroot U: Serum Thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 1994; 79: 98-105.
3. 131I uptakes after triiodothyronine withdrawal in patients with thyroid cancer. J Clin Endocrinol Metab 1981; 53: 1199-1206.
4. Montenegro J, González O, Saracho R, Aguirre R, González O, Martínez I: Changes in Renal Function in primary hypothyroidism. Am J Kidney Dis 1996; 27: 195-198.
5. Walton KW, Campbell DA, Tonks EL: The significance of alterations in serum lipids in thyroid dysfunction. Clin Sei 1965; 29: 199-215.
6. Crile G: The endocrine dependency of certain thyroid cancers and the danger that hypothroidism may stimulate their growth. Cancer 1957; 10: 1119-1137.
7. Soh EY, Sobhi SA, Wong MG, Meng YG, Siperstein AE, Clark OH, et al: Thyroid-stimulating hormone promotes the secretion of vascular endothelial growth factor in thyroid cancer cell lines. Surgery 1996; 120 (6): 944-947.
8. Hayashizaki Y, Miyai K, Kato K, Matsubara K: Molecular cloning of the human thyrotropin-bata subunit gene. FEBS Lett 1985; 188: 394-400.
9. Watanabe S, Hayashizaki Y, Endo Y, Hirono M, Takimoto N, Tamaki M, et al: Production of human thyroid-stimulating hormone in Chinese hamster ovary cells. Biochem Biophys Res Commun 1987; 149: 11491155.
10. Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, et al: A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab 2006; 91: 878-884.
11. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, et al: A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999; 84: 3877-3885.
12. Ladenson PW, Braverman LE, Mazzaferri EL, Davis FB, Cooper DS, Garber JR, et al: Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997; 337: 888-896.
13. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, et al: Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Metab 2006; 91: 926-932.
14. Meier CA, Braverman LE, Ebner SA, Veronikis I, Daniels GH, Ross DS, et al: Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab 1994; 78: 188-196.
15. Kim K, Johnson JA, Derendorf H: Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol 2004; 44:1083-1105.
16. Yasuda SU, Zhang L, Huang SM: The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 2008; 84: 417-423.
17. Naito C: Necessity and requirements of bridging studies and their present status in Japan, Int J Clin Pharmacol Ther 2000; 38: 80-86.
18. Billewicz WZ, Chapman RS, Crooks J, Day ME, Gossage J, Wayne SE, et al: Statistical methods applied to the diagnosis of hypothyroidism. Q J Med Apr 1969; 38: 255-266.